BioNTech tests new cancer drugs in first human trial
NCT ID NCT04710043
Summary
This was the first-ever study in people to test the safety and early effects of two new cancer drugs, BNT152 and BNT153, developed by BioNTech. It involved 86 adults with advanced solid tumors that had spread or could not be removed by surgery, and for whom standard treatments were no longer working. The main goal was to find safe dose levels and see how the drugs behaved in the body, while also checking for any early signs that the drugs might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Masaryk Memorial Cancer Institute
Brno, 65653, Czechia
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611, United States
-
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.